OBJECTIVE: To assess the pharmacodynamic effects of furosemide in pregnancy. METHODS: Twenty-one pregnant women who received furosemide 20 mg daily had cardiac output (CO), stroke volume (SV), and total peripheral resistance (TPR) measured by Doppler technique before and after treatment. RESULTS: Furosemide was initiated at 22.4 +/- 6.0 weeks gestation. CO and SV decreased (mean +/- SD: 1.2 +/- 0.2 L/min and 17+/-3 mL, respectively), whereas TPR increased (101+/-26 dyne.sec.cm(-5); p < 0.001 for all) after 2.9+/-1.4 weeks. Hemodynamics did not approach the expected mean for pregnancy. CONCLUSIONS: While furosemide improved the hyperdynamic circulation in pregnancy, it did not lower blood pressure or cause clinically significant vasoconstriction.
OBJECTIVE: To assess the pharmacodynamic effects of furosemide in pregnancy. METHODS: Twenty-one pregnant women who received furosemide 20 mg daily had cardiac output (CO), stroke volume (SV), and total peripheral resistance (TPR) measured by Doppler technique before and after treatment. RESULTS:Furosemide was initiated at 22.4 +/- 6.0 weeks gestation. CO and SV decreased (mean +/- SD: 1.2 +/- 0.2 L/min and 17+/-3 mL, respectively), whereas TPR increased (101+/-26 dyne.sec.cm(-5); p < 0.001 for all) after 2.9+/-1.4 weeks. Hemodynamics did not approach the expected mean for pregnancy. CONCLUSIONS: While furosemide improved the hyperdynamic circulation in pregnancy, it did not lower blood pressure or cause clinically significant vasoconstriction.
Authors: Kelsey McLaughlin; John W Snelgrove; Laura E Sienas; Thomas R Easterling; John C Kingdom; Catherine M Albright Journal: J Am Heart Assoc Date: 2022-03-14 Impact factor: 6.106